Scinai Completes Reorganization, Outlines Priorities

Scinai Immunotherapeutics has completed a strategic reorganization to establish a dedicated Contract Development and Manufacturing Organization (CDMO) platform and a streamlined R&D structure. The company has also outlined its priorities for 2026, focusing on enhancing its operational capabilities. This restructuring aims to improve efficiency and focus on core competencies within the biopharmaceutical sector. Scinai's move positions it to better serve clients needing specialized manufacturing and development services.